After attracting star CEO Hung, Axovant looks to raise $125m
Apr 13 2017
Over the last five trading sessions, the stock has moved 32.35%. The company has a consensus rating of "Buy" and a consensus target price of $25.32.
Other equities research analysts also recently issued reports about the company.
02/03/2016 - Axovant Sciences had its "conviction sell" rating reiterated by analysts at Chardan Capital.
The stock added in the prior trading session by 9.22%, closing at the stock price of $20.25.
On Monday shares of Axovant Sciences shot up by 22.54% to close the day at $18.54. Cowen and Company initiated coverage on Axovant Sciences in a report on Friday, February 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The stock now has a consensus rating of "Buy" and a consensus target price of $25.32. Axovant Sciences has a 12 month low of $10.69 and a 12 month high of $17.66. The company has a 50-day moving average price of $14.27 and a 200 day moving average price of $13.34.
However even a relatively modest success could open up a huge market for Axovant - a year ago analysts EP Vantage ranked the molecule as the most valuable unpartnered asset, estimating its net present value as $5.2 billion.
This showed the surprise of -4.3% in the last quarter earnings. That is what investors in Axovant Sciences are saying.
01/12/2017 - Axovant Sciences had its "outperform" rating reiterated by analysts at Oppenheimer. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and global trademark & copyright laws. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/04/12/axovant-sciences-ltd-axon-receives-overweight-rating-from-piper-jaffray-companies.html. During the past three month period the stock surged 56.01% and increased 46.53% in past six month.
In midmorning trading on the stock market today, Axovant stock popped 28.9%, near 19.50, after announcing that former Medivation CEO David Hung would succeed Vivek Ramaswamy at the top job at Axovant. Opus Point Partners Management LLC raised its position in shares of Axovant Sciences by 10.9% in the third quarter. The company reported its last quarter on 12/31/2016. Finally, Norges Bank acquired a new position in shares of Axovant Sciences during the fourth quarter valued at approximately $508,000.
In the liquidity ratio analysis; quick ratio for most recent quarter was 5.20 while current ratio for time period was 5.20. Artal Group S.A. now owns 300,000 shares of the company's stock worth $3,726,000 after buying an additional 50,000 shares during the last quarter.
06/07/2016 - Leerink Swann began new coverage on Axovant Sciences giving the company a "outperform" rating.